Emtricitabine/Tenofovir disoproxil Zentiva recommended by EMA CHMP as generic for Truvada in HIV treatment- Zentiva
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Emtricitabine/Tenofovir disoproxil Zentiva, from Zentiva, intended for the treatment of HIV infection. It will be available as 200 mg/245 mg film-coated tablets. Emtricitabine/Tenofovir disoproxil Zentiva is a generic of Truvada which has been authorised in the EU since 21 February 2005. Studies have demonstrated the satisfactory quality of Emtricitabine/Tenofovir disoproxil Zentiva, and its bioequivalence to the reference product Truvada.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins